Prostate Cancer

Black men with metastatic castration-resistant prostate cancer appear less likely to receive targeted therapies than white men, according to data published in JAMA Network Open.

CHICAGO — In this Healio video exclusive, Andrew Armstrong, MD, discusses the results of the use of abiraterone acetate and apalutamide plus prednisone in Black and White patients with metastatic castrate-resistant prostate cancer.

CHICAGO — In this Healio video exclusive, Andrew Armstrong, MD, discusses his presentation from the Genitourinary Cancer session at the ASCO Annual meeting.

CHICAGO — In this Healio video exclusive, Silke Gillessen, MD, discusses a study that confirms the triplet combination in de novo, low-volume, metastatic, castration-sensitive prostate cancer as the best course of action.

More than half of men treated for metastatic prostate cancer reported experiencing some degree of financial hardship, according to study results published in The Journal of Urology.

Researchers have discovered a biological mechanism among men with diabetes and metastatic prostate cancer that they believe may lay the foundation for better testing and treatments for Black men with both diseases.

Shared decision-making could attenuate racial disparities in prostate cancer screening, according to research published in the American Journal of Preventive Medicine.

Prostate cancer is a complex cancer, with patients who present differently with various clinical staging and criteria; thus, follow-up care after treatment also differs among this patient population.

The combination of cabozantinib and atezolizumab prolonged PFS compared with second novel hormonal therapy for men with metastatic castration-resistant prostate cancer, according to a topline data announcement.

CHICAGO — In this video, Stephen J. Freedland, MD, discusses how intensification of androgen deprivation therapy using novel hormonal therapies remains underutilized in patients with de novo metastatic castration-sensitive prostate cancer.